Sinovac Biotech (SVA) said late Thursday it received a notification from Nasdaq informing the Chinese biopharmaceutical company of non-compliance with a listing rule related to the delayed filing of its 2024 annual report.
The company has until July 15 to submit a plan to regain compliance. If Nasdaq accepts the plan, Sinovac could be granted an extension until Nov. 11 to regain compliance.
The company's audit committee is "actively searching" for a new auditor following the previously disclosed resignation of Grant Thornton Zhitong Certified Public Accountants.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。